Yankees Bring Back All-Star Jazz Chisholm, Place Luke Weaver on IL in Massive Roster Move
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The New York Yankees have made a massive roster move, activating All-Star infielder Jazz Chisholm Jr. from his rehab assignment and off the 10-day injured list, and adding reliever Luke Weaver to the 15-day IL, among other transactions.
Right-hander Fernando Cruz has been reinstated from the injured list, right-hander Yerry de los Santos was recalled from Triple-A, Jorbit Vivas was optioned to Triple-A, and right-hander Carlos Carrasco was designated for assignment.
Jazz Chisholm Jr. #13 of the New York Yankees slides into third base after advancing on an error after hitting a double in the first inning against the Baltimore Orioles at Oriole Park at Camden...
Jazz Chisholm Jr. #13 of the New York Yankees slides into third base after advancing on an error after hitting a double in the first inning against the Baltimore Orioles at Oriole Park at Camden Yards on April 29, 2025 in Baltimore, Maryland. Chisholm left the game after the play with an injury. More
Photo byMore news: Yankees Lose Star Pitcher for Summer Months After Injury Diagnosis
Prior to tonight's game, the Yankees made the following roster moves:
• Returned INF Jazz Chisholm Jr. (#13) from his rehab assignment and reinstated him from the 10-day injured list.
• Reinstated RHP Fernando Cruz (#63) from the 15-day injured list.
• Recalled RHP Yerry de… — New York Yankees (@Yankees) June 3, 2025
Chisholm last played on April 29, before a right oblique strain sidelined him for what would turn into the entirety of May. After three rehab games in Double-A, the infielder looks ready to return to the diamond.
Weaver recently suffered a hamstring injury while warming up on Sunday against the Los Angeles Dodgers. ESPN's Jeff Passan reported that an MRI revealed he could miss four to six weeks of action.
The right-hander has been electric for New York this season, posting a 1.05 ERA across 25.2 frames of work, allowing just three runs in this time. He has 24 strikeouts in as many outings to just seven walks on the year.
It appears that Devin Williams will go back to his role as closer amid Weaver's absence. The struggling Williams has a 6.23 ERA across 21.2 innings pitched this season and will have to take a major step up with the increased workload.
There will be more bullpen help on the way as Cruz will continue to build upon his 2.66 ERA over 23.2 frames this season. The right-hander has an ERA+ of 150 this season, ranking him 50 percent better than qualified pitchers as he looks to get back to his first season as a Yankee.
De los Santos will also look to take on a larger role, as he has allowed four runs in 12 innings of work in Pinstripes. He has dazzled the mound in 10.1 frames in Triple-A with a 1.74 ERA, striking out 11 batters and walking four.
Vivas split time across second and third base since the beginning of May, but was struggling at the plate with a .156 batting average across 45 at-bats. The 24-year-old heads back to Triple-A, where he was hitting .319 before his call-up.
The right-handed veteran Carrasco struggled in his eight appearances for the Yankees as he allowed 21 runs in 32 innings. The 38-year-old will look for another opportunity to extend his 16-year MLB career.
More news: Mets Promote Former Top Prospect vs Dodgers Amid Mark Vientos Injury: Reports
For more MLB news, visit Newsweek Sports.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
USA Today
33 minutes ago
- USA Today
D'Andre Swift shares first impression of Bears rookie Kyle Monangai
D'Andre Swift shares first impression of Bears rookie Kyle Monangai The Chicago Bears didn't make any major moves at running back this offseason, with the only addition coming with the selection of Kyle Monangai out of Rutgers in the seventh round of the 2025 NFL draft. Adding Monangai to the running back room, which will feature new position coach Eric Bieniemy, brings plenty of eyes and attention to every running back on the roster, especially D'Andre Swift. In what many, including himself, felt was a disappointing 2024 season, Swift not only vows to bounce back, but is also ready to be a mentor for his rookie teammate. Swift had high praise for Monangai, a two-time All-Big Ten selection in 2023 and 2024, and what he's done so far this offseason. "Real good, really good. Really excited for him," Swift said. "Very talented, very talented. He's cool, and he's from Jersey. I'm from Philly, he's from Jersey, so close. But he's been really good so far, excited for him." While there could be an opportunity to crack into the rotation as a rookie, it's equally as important to see the veteran Swift speak highly of him early in the offseason program. With Swift, Roschon Johnson, and Monangai, head coach Ben Johnson will have plenty of options and opportunities to utilize all three backs, who all have a different style of play and running ability. Follow Bears Wire on Twitter, Facebook and Instagram
Yahoo
35 minutes ago
- Yahoo
Podcast: Is 2025 the right time for Houston to make a superstar trade?
With general manager Rafael Stone calling the shots, are the Houston Rockets ready to make a star-level trade in the NBA's 2025 offseason? Hosted by credentialed media members Jackson Gatlin and Ben DuBose, this week's episode of Locked on Rockets runs through the pros and cons of various scenarios. Advertisement Among the All-Star names discussed include Milwaukee Bucks forward Giannis Antetokounmpo; Boston Celtics guard Jaylen Brown; and guard Devin Booker and forward Kevin Durant, each of the Phoenix Suns. Discussion topics include what the hypothetical trades might look like, as well as potential sticking points in each negotiation — depending on what the surrounding roster would look like. The show also explores the potential use of Fred VanVleet's expiring contract as a trade asset, particularly in the weeks leading up to the June 29 deadline to decide on his 2025-26 team option. But, do the Rockets need to make a big move, at all? With Houston coming off a regular season with the NBA's fourth-best record, it's quite plausible that Stone and the Rockets might simply stay the course with a relatively young roster that should continue to improve, organically. Relative to 2023-24, the Rockets improved from 41-41 and No. 11 in the Western Conference to 52-30 and No. 2 in the 2024-25 West standings. A similar bump in 2025-26 could lift Houston to the tier of legitimate title contenders. Advertisement With that in mind, Locked on Rockets runs through all the scenarios. Watch and/or take a listen! More: Rockets, Fred VanVleet delay deadline for 2025-26 contract decision This article originally appeared on Rockets Wire: Podcast: Is 2025 the right time for Houston to make a superstar trade?
